CRISPR Therapeutics has been granted a patent for masked chimeric antigen receptor (CAR) constructs targeting tyrosine-protein kinase-like 7 (PTK7). The masked CAR includes an antigen binding domain and a mask peptide to prevent binding until cleaved. Genetically engineered T cells expressing this CAR have therapeutic potential. GlobalData’s report on CRISPR Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights CRISPR Therapeutics AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on CRISPR Therapeutics, CRISPR genome editing was a key innovation area identified from patents. CRISPR Therapeutics's grant share as of April 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.

Masked car construct targeting ptk7 for t cell therapy

Source: United States Patent and Trademark Office (USPTO). Credit: CRISPR Therapeutics AG

A recently granted patent (Publication Number: US11926676B2) discloses a masked chimeric antigen receptor (CAR) specific to tyrosine-protein kinase-like 7 (PTK7). The masked CAR includes an extracellular antigen binding domain with a single chain variable fragment (scFv) that binds PTK7, along with a mask peptide linked to the scFv via a protease cleavage site. The mask peptide, which is 13-25 amino acids in length, can be removed by protease cleavage at the site, which is a cleavage site of a matrix metalloproteinase (MMP), specifically MMP14 with the motif of PLGLA (SEQ ID NO: 15). Additionally, the masked CAR contains intracellular signaling domains, including co-stimulatory domains like CD28 or 4-1BB, and a transmembrane domain, such as CD8, for enhanced functionality.

Moreover, the patent covers a nucleic acid encoding the masked CAR, genetically engineered T cells expressing the masked CAR, and methods for producing these engineered CAR-T cells. The genetically engineered T cells may have disrupted TRAC or B2M genes, with the nucleic acid encoding the masked CAR inserted to disrupt TRAC gene expression. The patent also includes a population of genetically engineered T cells expressing the masked CAR, highlighting the potential for therapeutic applications in cancer treatment. The method for producing these CAR-T cells involves delivering the nucleic acid encoding the masked CAR to T cells and generating genetically engineered CAR-T cells expressing the masked CAR, offering a promising approach in the field of immunotherapy.

To know more about GlobalData’s detailed insights on CRISPR Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies